- Home
- TACT vs VRNA Comparison
TACT vs VRNA Comparison
Compare TACT & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TACT
- VRNA
- Stock Information
- Founded
- TACT 1996
- VRNA 2005
- Country
- TACT United States
- VRNA United Kingdom
- Employees
- TACT N/A
- VRNA N/A
- Industry
- TACT Computer peripheral equipment
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- TACT Technology
- VRNA Health Care
- Exchange
- TACT Nasdaq
- VRNA Nasdaq
- Market Cap
- TACT 35.7M
- VRNA 7.8B
- IPO Year
- TACT 1996
- VRNA 2017
- Fundamental
- Price
- TACT $3.67
- VRNA $98.17
- Analyst Decision
- TACT Strong Buy
- VRNA Strong Buy
- Analyst Count
- TACT 1
- VRNA 8
- Target Price
- TACT $5.00
- VRNA $105.38
- AVG Volume (30 Days)
- TACT 15.2K
- VRNA 1.4M
- Earning Date
- TACT 08-07-2025
- VRNA 08-07-2025
- Dividend Yield
- TACT N/A
- VRNA N/A
- EPS Growth
- TACT N/A
- VRNA N/A
- EPS
- TACT N/A
- VRNA N/A
- Revenue
- TACT $45,750,000.00
- VRNA $118,535,000.00
- Revenue This Year
- TACT $14.81
- VRNA $891.79
- Revenue Next Year
- TACT N/A
- VRNA $78.94
- P/E Ratio
- TACT N/A
- VRNA N/A
- Revenue Growth
- TACT N/A
- VRNA N/A
- 52 Week Low
- TACT $3.12
- VRNA $14.14
- 52 Week High
- TACT $5.11
- VRNA $97.17
- Technical
- Relative Strength Index (RSI)
- TACT 45.15
- VRNA 78.68
- Support Level
- TACT $3.46
- VRNA $89.69
- Resistance Level
- TACT $3.83
- VRNA $94.45
- Average True Range (ATR)
- TACT 0.19
- VRNA 3.18
- MACD
- TACT -0.01
- VRNA 0.46
- Stochastic Oscillator
- TACT 34.62
- VRNA 95.35
About TACT TransAct Technologies Incorporated
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.